Anna Compagnoni

1.2k total citations
19 papers, 840 citations indexed

About

Anna Compagnoni is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Anna Compagnoni has authored 19 papers receiving a total of 840 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Molecular Biology, 7 papers in Oncology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Anna Compagnoni's work include Renal cell carcinoma treatment (2 papers), Renal and related cancers (2 papers) and Cancer Immunotherapy and Biomarkers (2 papers). Anna Compagnoni is often cited by papers focused on Renal cell carcinoma treatment (2 papers), Renal and related cancers (2 papers) and Cancer Immunotherapy and Biomarkers (2 papers). Anna Compagnoni collaborates with scholars based in Italy, United States and United Kingdom. Anna Compagnoni's co-authors include Andrea Giovagnoni, Daniela Garavaglia, Valter Torri, Eliana Rulli, Luca Salvolini, Irene Floriani, Michael B. Atkins, Hirotsugu Uemura, Fiona Thistlethwaite and Paul B. Robbins and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Lancet Oncology.

In The Last Decade

Anna Compagnoni

19 papers receiving 828 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anna Compagnoni Italy 13 351 207 198 180 119 19 840
T G Allen-Mersh United Kingdom 17 377 1.1× 123 0.6× 92 0.5× 130 0.7× 57 0.5× 31 831
Jin‐Yu Sun China 17 216 0.6× 113 0.5× 107 0.5× 290 1.6× 41 0.3× 40 774
Clare Pattenden United Kingdom 14 501 1.4× 155 0.7× 115 0.6× 162 0.9× 41 0.3× 21 902
Shiyou Wei China 18 158 0.5× 245 1.2× 137 0.7× 255 1.4× 33 0.3× 53 921
Leung Li Hong Kong 14 209 0.6× 104 0.5× 151 0.8× 132 0.7× 23 0.2× 33 571
Nikolaos Charalampakis Greece 12 511 1.5× 305 1.5× 56 0.3× 270 1.5× 83 0.7× 42 988
Rachel Goodwin Canada 20 894 2.5× 307 1.5× 81 0.4× 212 1.2× 97 0.8× 87 1.2k
Radek Kučera Czechia 19 309 0.9× 270 1.3× 38 0.2× 281 1.6× 60 0.5× 94 1.0k
Bo Lan China 14 619 1.8× 328 1.6× 47 0.2× 173 1.0× 97 0.8× 54 919

Countries citing papers authored by Anna Compagnoni

Since Specialization
Citations

This map shows the geographic impact of Anna Compagnoni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Compagnoni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Compagnoni more than expected).

Fields of papers citing papers by Anna Compagnoni

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Compagnoni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Compagnoni. The network helps show where Anna Compagnoni may publish in the future.

Co-authorship network of co-authors of Anna Compagnoni

This figure shows the co-authorship network connecting the top 25 collaborators of Anna Compagnoni. A scholar is included among the top collaborators of Anna Compagnoni based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Compagnoni. Anna Compagnoni is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Daver, Naval, Naveen Pemmaraju, Mikkael A. Sekeres, et al.. (2024). Phase 2 Multicenter Trial of Tagraxofusp in Combination with Venetoclax and Azacitidine in Adults with Previously Untreated CD123+ Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy. Blood. 144(Supplement 1). 4265.1–4265.1. 1 indexed citations
2.
3.
Gibb, Adam, Graham P. Collins, Rakesh Popat, et al.. (2017). BLOCKADE OF THE PD‐1 CHECKPOINT WITH ANTI–PD‐L1 ANTIBODY AVELUMAB IS SUFFICIENT FOR CLINICAL ACTIVITY IN RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA (CHL). Hematological Oncology. 35(S2). 67–67. 31 indexed citations
4.
Choueiri, Toni K., James Larkin, Mototsugu Oya, et al.. (2017). First-line avelumab + axitinib therapy in patients (pts) with advanced renal cell carcinoma (aRCC): Results from a phase Ib trial.. Journal of Clinical Oncology. 35(15_suppl). 4504–4504. 32 indexed citations
5.
Ferrari, Antonio, et al.. (2016). Evaluation of the Effects of CHF6001, an Inhaled PDE4 Inhibitor, on Cardiac Repolarization and Cardiac Arrhythmias in Healthy Volunteers. Journal of Cardiovascular Pharmacology. 68(1). 41–48. 2 indexed citations
6.
Acerbi, Daniela, et al.. (2013). Safety, tolerability and pharmacokinetics of a new inhaled once-daily phosphodiesterase (PDE) 4 inhibitor in healthy volunteers. European Respiratory Journal. 42(Suppl 57). P736–P736. 1 indexed citations
7.
Baldo, Paolo, Maurizio Rupolo, Anna Compagnoni, et al.. (2010). Interferon-alpha for maintenance of follicular lymphoma. Cochrane Database of Systematic Reviews. CD004629–CD004629. 25 indexed citations
8.
Floriani, Irene, Valter Torri, Eliana Rulli, et al.. (2009). Performance of imaging modalities in diagnosis of liver metastases from colorectal cancer: A systematic review and meta‐analysis. Journal of Magnetic Resonance Imaging. 31(1). 19–31. 174 indexed citations
9.
Frapolli, Roberta, Massimo Zucchetti, Cristiana Sessa, et al.. (2009). Clinical pharmacokinetics of the new oral camptothecin gimatecan: The inter-patient variability is related to α1-acid glycoprotein plasma levels. European Journal of Cancer. 46(3). 505–516. 7 indexed citations
10.
Moja, Lorenzo, Ivan Moschetti, Anna Compagnoni, et al.. (2009). Compliance of clinical trial registries with the World Health Organization minimum data set: a survey. Trials. 10(1). 56–56. 47 indexed citations
11.
Bużańska, Leonora, Joanna Sypecka, Silvia Nerini‐Molteni, et al.. (2009). A Human Stem Cell-Based Model for Identifying Adverse Effects of Organic and Inorganic Chemicals on the Developing Nervous System. Stem Cells. 27(10). 2591–2601. 94 indexed citations
12.
13.
Moja, Lorenzo, et al.. (2008). Trastuzumab containing regimens for early breast cancer (Protocol). 1 indexed citations
14.
Marabese, Mirko, Sergio Marchini, Dario Cattaneo, et al.. (2007). Expression levels of p53 and p73 isoforms in stage I and stage III ovarian cancer. European Journal of Cancer. 44(1). 131–141. 29 indexed citations
15.
Marchini, Sergio, Mirko Marabese, Dario Cattaneo, et al.. (2007). ΔNp63 expression is associated with poor survival in ovarian cancer. Annals of Oncology. 19(3). 501–507. 35 indexed citations
16.
Apolone, Giovanni, Anna Compagnoni, Paola Mosconi, et al.. (2006). A Multidisciplinary Project to Improve the Quality of Cancer Pain Management in Italy. Journal of Ambulatory Care Management. 29(4). 332–341. 19 indexed citations
17.
Perrone, Christopher, et al.. (2004). Central pontine myelinolysis induced by hypophosphatemia following Wernicke?s encephalopathy. Neurological Sciences. 24(6). 407–410. 28 indexed citations
18.
Stroffolini, Tommaso, et al.. (1995). High prevalence of hepatitis C virus infection in a small central Italian town: lack of evidence of parenteral exposure.. PubMed. 27(5). 235–8. 92 indexed citations
19.
Compagnoni, Anna, et al.. (1972). [Therapy of gout attacks with synthetic delayed-action ACTH].. PubMed. 77(6). 322–32. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by T G Allen-Mersh Breakdown of academic impact, for papers by Jin‐Yu Sun Breakdown of academic impact, for papers by Clare Pattenden Breakdown of academic impact, for papers by Shiyou Wei Breakdown of academic impact, for papers by Leung Li Breakdown of academic impact, for papers by Nikolaos Charalampakis Breakdown of academic impact, for papers by Rachel Goodwin Breakdown of academic impact, for papers by Radek Kučera Breakdown of academic impact, for papers by Bo Lan
Rankless by CCL
2026